|
KMID : 0854720090290020127
|
|
Korean Journal of Asthma, Allergy and Clinical Immunology
2009 Volume.29 No. 2 p.127 ~ p.131
|
|
|
Successful Desensitization to Epirubicin in a Breast Cancer Patient with Doxorubicin Hypersensitivity
|
|
Park Han-Ki
Kim Min-Hye
Lim Kyung-Whan
Kang Min-Koo
Kim Byung-Keun
Kim Tae-Wan
Kwon Jae-Woo
Lee So-Hee
Lee Sang-Min
Kim Se-Hoon
Park Heung-Woo
Cho Sang-Heon
Min Kyung-Up
Kim You-Young
Kim Jee-Hyun
Chang Yoon-Seok
|
|
|
Abstract
|
|
|
|
Doxorubicin, a chemotherapeutic agent of the anthracycline family, has commonly been used to treat a wide range of cancers including leukemia, Hodgkin’s lymphoma, and cancers of the breast, uterus, ovary and bladder. Hypersensitivity is a rare adverse reaction to anthracyclines including daunorubicin, idarubicin and epirubicin. Although cross-reactivity among chemotherapeutic agents of the anthracycline family is not completely established, these agents are not clinically recommended if a patient has show hypersensitivity reaction to any anthracyclines. Desensitization is an alternative treatment option to overcome hypersensitivity reaction to anthracyclines, but cases of anthracycline desensitization have rarely been reported till now. We report successful epirubucin desensitization in a breast cancer patient with doxorubicin hypersensitivity.
|
|
|
KEYWORD
|
|
|
Desensitization, Epirubicin, Hypersensitivity
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
  
|